Holen Sie sich die Stockscreener-App
9.23
1.96%
-0.18
Schlusskurs vom Vortag:
$9.41
Offen:
$9.52
24-Stunden-Volumen:
197.44K
Relative Volume:
0.43
Marktkapitalisierung:
$1.23B
Einnahmen:
$53.99M
Nettoeinkommen (Verlust:
$-222.30M
KGV:
-5.0809
EPS:
-1.8166
Netto-Cashflow:
$-213.50M
1W Leistung:
-6.44%
1M Leistung:
-6.25%
6M Leistung:
+58.51%
1J Leistung:
+104.10%
1-Tages-Spanne:
$9.13
$9.83
1-Wochen-Bereich:
$9.13
$10.62
52-Wochen-Spanne:
$3.30
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
9.21 | 1.26B | 53.99M | -222.30M | -213.50M | -1.8166 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.17 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.65 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.99 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.40 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.66 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-05-28 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
| 2020-11-20 | Eingeleitet | BofA Securities | Buy |
| 2020-09-22 | Eingeleitet | Goldman | Buy |
| 2020-07-27 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-24 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Immatics N V Aktie (IMTX) Neueste Nachrichten
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate - Yahoo Finance Singapore
Can Immatics NV Equity Warrant generate free cash flow2026 Market Sentiment & Target Return Focused Stock Picks - baoquankhu1.vn
Immatics (NASDAQ:IMTX) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Immatics (NASDAQ:IMTX) Shares Gap DownTime to Sell? - MarketBeat
Is Immatics’ 2025 Loss and PRAME Pipeline Push Altering The Investment Case For Immatics (IMTX)? - simplywall.st
Jefferies Financial Group Inc. Takes $10.18 Million Position in Immatics N.V. $IMTX - MarketBeat
Insider Buy: What is the target price for Immatics NV stockDay Trade & Real-Time Volume Triggers - baoquankhu1.vn
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX) - Seeking Alpha
Immatics NV earnings beat by €0.13, revenue topped estimates - Investing.com Nigeria
Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to "Hold" - MarketBeat
Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to “Hold” - Defense World
Is Immatics N.V. Equity Warrant stock near bottom after declineGold Moves & Low Risk Growth Stock Ideas - Naître et grandir
Tech Rally: Should I invest in Immatics NV Equity Warrant before earnings2025 Momentum Check & Short-Term Swing Trade Alerts - baoquankhu1.vn
Immatics 2025 Financial Results: Q4 Revenue $23M, Annual Loss $222.2MNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Immatics (NASDAQ:IMTX) Announces Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Immatics Announces Full Year 2025 Financial Results and Business Update - Investing News Network
Immatics: Fourth Quarter Financial Overview - Bitget
Immatics: Q4 Earnings Snapshot - KVUE
Immatics (IMTX) Projects Promising Developments for 2026 After R - GuruFocus
Immatics Confirms 2027 Anzu-cel Launch Timeline as PRAME Franchise and Cash Runway Advance - TipRanks
Immatics Earnings Report: Q4 Overview - Benzinga
Immatics (NASDAQ: IMTX) 2025 results show revenue drop and larger net loss - Stock Titan
immatics biotechnologies GmbH (IMTXW) Competitors - Meyka
(IMTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Immatics (NASDAQ:IMTX) Lowered to “Sell” Rating by Wall Street Zen - Defense World
IMTX SEC FilingsImmatics N.V 10-K, 10-Q, 8-K Forms - Stock Titan
Immatics (NASDAQ:IMTX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Immatics N.V. (NASDAQ:IMTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Trade Report: Is PACK a defensive stockWeekly Trading Summary & Advanced Technical Signal Analysis - baoquankhu1.vn
Energy Moves: Is Immatics NV in a long term uptrendPortfolio Risk Summary & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Immatics (NASDAQ:IMTX) Trading Down 5% – Here’s What Happened - Defense World
IMTX PE Ratio & Valuation, Is IMTX Overvalued - Intellectia AI
Is Immatics N.V. a defensive stockQuarterly Trade Report & High Accuracy Swing Entry Alerts - mfd.ru
Aug Gainers: Whats next for Immatics NV Equity Warrant stockTrade Analysis Report & AI Driven Stock Price Forecasts - baoquankhu1.vn
Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to Hold - MarketBeat
Immatics N.V. (IMTX): Investor Outlook Reveals an 85% Upside Potential Amidst Groundbreaking Cancer Therapies - DirectorsTalk Interviews
RTW INVESTMENTS, LP Increases Stake in Immatics NV - GuruFocus
Can Immatics N.V. Equity Warrant expand into new marketsEarnings Recap Report & Smart Swing Trading Techniques - mfd.ru
Can Immatics N.V. Equity Warrant reach resistance levels soonJuly 2025 Chart Watch & Risk Controlled Stock Pick Alerts - mfd.ru
Will Immatics N.V. (4A3) stock gain from green policiesBuy Signal & Reliable Momentum Entry Alerts - mfd.ru
Immatics (NASDAQ:IMTX) Shares Down 5%Time to Sell? - MarketBeat
Liquidity Mapping Around (IMTX) Price Events - Stock Traders Daily
Exit Recap: Is Immatics NV a cyclical or defensive stockPortfolio Gains Report & Real-Time Market Trend Scan - baoquankhu1.vn
RTW Investments reveals 8.5% Immatics N.V. (IMTX) stake in Schedule 13G/A - Stock Titan
Institution Moves: Is Flushing Financial Corporation attractive at current valuationQuarterly Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
What Immatics (IMTX)'s Melanoma Orphan Drug Designation Means For Shareholders - Sahm
Immatics N.V. (IMTX) Stock Analysis: Near 93% Upside Potential Drives Investor Interest - DirectorsTalk Interviews
Does Immatics N.V. stock have upside surprise potentialQuarterly Earnings Report & Daily Technical Forecast Reports - mfd.ru
Can Immatics N.V. Equity Warrant be the next market leader2025 Key Highlights & Consistent Income Trade Ideas - mfd.ru
Immatics (IMTX) Receives FDA Orphan Status for Melanoma Treatmen - GuruFocus
Whale Trades: Will Immatics NV Equity Warrant benefit from government policyJuly 2025 News Drivers & Low Risk Entry Point Guides - baoquankhu1.vn
Finanzdaten der Immatics N V-Aktie (IMTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):